跳至主要内容
临床试验/ACTRN12623000987662
ACTRN12623000987662进行中(未招募)Unknown

Managing cancer and living meaningfully (CALM) in people with non-small cell lung cancer treated with novel therapies: a pilot study

Peter MacCallum Cancer Centre0 个研究点目标入组 19 人开始时间: 2023年9月11日最近更新:
适应症

试验速览

阶段
Unknown
状态
进行中(未招募)
发起方
入组人数
19

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional
分配方式
Non-randomised trial
主要目的
Treatment
盲法
Open (masking not used)

入排标准

年龄范围
18 Years 至 o limit(—)
性别
All

入选标准

  • at least 18 years old;
  • diagnosis of locally advanced NSCLC or metastatic NSCLC;
  • currently or previously receiving immunotherapy or targeted therapy and at least 6 months post initiation of IT (such as pembrolizumab, atezolizumab, nivolumab) or TT (such as TT directed at EGFR, ALK, ROS1, BRAF, MEK or RET) or combination chemotherapy/immunotherapy;
  • expected prognosis of at least 6 months (to allow for completion of therapy);
  • able to read and write in English.
  • able to commit to 3-6 sessions.

排除标准

  • major communication difficulties;
  • cognitive impairment on the basis of a Short Orientation-Memory-Concentration Test (SOMCT) of 7 or more or indicated by the clinical team or medical file
  • patients currently receiving formal psychological therapy.

研究者

发起方
Peter MacCallum Cancer Centre

相似试验